Role of TET2 mutations in myeloproliferative neoplasms

Current Hematologic Malignancy Reports

Volumn 7, Issue 1, 2012, Pages 57-64

  Pronier, Elodie ^b,c   Delhommeau, Francois ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

5 hydroxymethylcytosine; Epigenetics; Mutations; Myeloid malignancies .Hematopoietic stem cells; Myeloproliferative neoplasms; Pathogenesis; TET2

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; ONCOPROTEIN; PROTEIN TET2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; TET2 PROTEIN, HUMAN; TET2 PROTEIN, MOUSE;

ARTICLE; CARCINOGENESIS; EPIGENETICS; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR GENETICS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PROGNOSIS; PROTEIN FUNCTION; ANIMAL; DISEASE MODEL; GENETICS; MOUSE; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE FREQUENCY; HEMATOPOIESIS; HUMANS; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS;

EID: 84859229392     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0108-8     Document Type: Article

References (77)

1. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat RevCancer. 2004;4:143-53. (Pubitemid 38198742)
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-7. (Pubitemid 29070360)
3. Bird A. The essentials of DNA methylation. Cell. 1992;70:5-8.
4. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet. 1997;13:444-9. (Pubitemid 27479903)
5. Siegfried Z, Cedar H. DNA methylation: A molecular lock. Curr Biol. 1997;7:R305-7. (Pubitemid 27195597)
6. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929-30.
7. Tahiliani M, Koh KP, Shen Y, et al.: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNAby MLL partner TET1. Science 2009;324:930-935. Discovery of TET1 catalytic activity by homology with the trypanosome enzymes JBP1 and JBP2. Tahiliani et al. demonstrate for the first time the ability of a mammalian dioxygenase to convert 5-mC into 5-hmC.
8. Lorsbach RB, Moore J, Mathew S, et al. Tet1, a member of a novel protein family, is fused to mll in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17:637-41. (Pubitemid 36395661)
9. Ito S, D'Alessio AC, Taranova OV, et al.: Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell massspecification. Nature 2010;466:1129-1133. Ito et al. show that Tet1, Tet2, and Tet3 share the same catalytic activity and play a role in the transcription control of development genes.
10. Delhommeau F, Dupont S, Della Valle V, et al.: Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-2301. First evidence for mutations in TET2 in myeloid malignancies, including MPN. Shows a selective advantage of TET2 mutant cells over TET2 wild-type cells in severe combined immunodeficiency repopulation assays.
11. Langemeijer SM, Kuiper RP, Berends M, et al.: Acquiredmutations in TET2 are common in myelodysplastic syndromes.Nat Genet 2009;41:838-842. Large study of TET2 mutations in MDS and TET2 expression studies. Evidence for the modulation of TET2 during granulocytic differentiation.
12. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23:900-4.
13. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009;23:1343-5.
14. Tefferi A, Pardanani A, Lim KH, et al. Tet2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemiaand myelofibrosis. Leukemia. 2009;23:905-11.
15. Ko M, Huang Y, Jankowska AM, et al.: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant tet2. Nature2010;468:839-843. Evidence that patients with TET2 mutations have low 5-hmC levels and an abnormal DNA methylation profile.
16. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of theWorld Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51.
17. Vardiman JW. Chronic myelogenous leukemia, bcr-abl1+. Am JClin Pathol. 2009;132:250-60.
18. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2010;29:573-82.
19. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase jak2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61. (Pubitemid 40386783)
20. James C, Ugo V, Le Couedic JP, et al. A unique clonal jak2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-8. (Pubitemid 40663494)
21. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of jak2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-90. (Pubitemid 40570926)
22. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase jak2 in polycythemia vera, essential thrombocythemia,and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-97. (Pubitemid 40544655)
23. Scott LM, Tong W, Levine RL, et al. Jak2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med.2007;356:459-68. (Pubitemid 46193073)
24. Pardanani AD, Levine RL, Lasho T, et al. Mpl515 mutations in myeloproliferative and other myeloid disorders: a study of 1182patients. Blood. 2006;108:3472-6.
25. Pikman Y, Lee BH, Mercher T, et al. Mplw515l is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
26. Jager R, Gisslinger H, Passamonti F, et al. Deletions of the transcriptionfactor ikaros in myeloproliferative neoplasms. Leukemia. 2010;24:1290-8.
27. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein lnk drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116:988-92.
28. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy inmyeloproliferative neoplasms. Blood. 2009;113:6182-92.
29. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362:369-70.
30. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42:722-6.
31. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183-6.
32. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.Blood. 2009;114:144-7.
33. Viguie F, Aboura A, Bouscary D, et al. Common 4q24 deletion in four cases of hematopoietic malignancy: Early stem cell involvement? Leukemia. 2005;19:1411-5. (Pubitemid 41136336)
34. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117:e198-206.
35. Roche-Lestienne C, Marceau A, Labis E, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011;25(10):1661-4.
36. Olcaydu D, Rumi E, Harutyunyan A, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2010;96:367-74.
37. Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferativeneoplasms. Blood. 2009;114:1628-32.
38. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression ofmyeloproliferative neoplasms. Blood. 2010;115:2003-7.
39. Koh KP, Yabuuchi A, Rao S, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell. 2011;8:200-13.
40. Clouaire T, de Las Heras JI, Merusi C, Stancheva I. Recruitment of MBD1 to target genes requires sequence-specific interaction of theMBD domain with methylated DNA. Nucleic Acids Res.2010;38:4620-34.
41. Nakao M, Matsui S, Yamamoto S, et al. Regulation of transcription and chromatin by methyl-CPG binding protein MBD1. Brain Dev. 2001;23 Suppl 1:S174-6.
42. Young SR, Skalnik DG. CXXC finger protein 1 is required for normal proliferation and differentiation of the PLB-985 myeloidcell line. DNA Cell Biol. 2007;26:80-90. (Pubitemid 46363873)
43. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-44.
44. Ward PS, Patel J, Wise DR, et al. The common feature of leukemiaassociatedidh1 and idh2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell.2010;17:225-34.
45. Figueroa ME, Abdel-Wahab O, Lu C, et al.: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-567. Evidence that IDH1/2 and TET2 mutations impair hematopoietic differentiation in a similar way.
46. Ito S, Shen L, Dai Q, et al. TET proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300-3.
47. Pronier E, Almire C,Mokrani H, et al.: Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbserythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011;118:2551-2555. Demonstration that MPN patients with TET2 mutations have low DNA contents of 5-hmC, and that TET2 depletion in human progenitors leads to abnormal myeloid differentiation.
48. Klose RJ, Bird AP. Genomic DNA methylation: the mark and itsmediators. Trends Biochem Sci. 2006;31:89-97. (Pubitemid 43221841)
49. Penn NW, Suwalski R, O'Riley C, et al. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem J. 1972;126:781-90.
50. Li W, Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids. 2011;2011:870726.
51. Ficz G, Branco MR, Seisenberger S, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. 2011;473:398-402.
52. Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature.2011;473:394-7.
53. Robertson J, Robertson AB, Klungland A. The presence of 5-hydroxymethylcytosine at the gene promoter and not in the genebody negatively regulates gene expression. Biochem Biophys Res Commun. 2011;411:40-3.
54. Stroud H, Feng S, Morey Kinney S, et al. 5-hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonicstem cells. Genome Biol. 2011;12:R54.
55. Szulwach KE, Li X, Li Y, et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet. 2011;7:e1002154.
56. Williams K, Christensen J, Pedersen MT, et al.: TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011;473:343-348. Mapping of 5-hmC and TET1 localization: consequences for transcription and methylation.
57. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferaseDNMT1. Cancer Res. 2007;67:946-50.
58. Jin SG, Kadam S, Pfeifer GP. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosineand 5-hydroxymethylcytosine. Nucleic Acids Res. 2010;38:e125.
59. Guo JU, Su Y, Zhong C, et al. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain.Cell. 2011;145:423-34.
60. Cortellino S, Xu J, Sannai M, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deaminationbase excision repair. Cell. 2011;146:67-79.
61. Quivoron C, Couronne L, Della Valle V, et al.: Tet2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38. Description of two Tet2 gene-disrupted mouse models with dramatic consequences on HSCs and both myeloidand lymphoid differentiations. First description of TET2 mutations in human B and T lymphomas.
62. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11-24.
63. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17):4509-18.
64. Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (tet2) negatively regulates homeostasis and differentiation of hematopoieticstem cells in mice. Proc Natl Acad Sci U S A. 2011;108:14566-71.
65. Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803-10.
66. Grossmann V, Kohlmann A, Eder C, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011;25:877-9.
67. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification ofacute myeloid leukemia: a Cancer And Leukemia Group B study. J Clin Oncol. 2011;29:1373-81.
68. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemiaachieving complete remission. Blood. 2010;116:1132-5.
69. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloidleukemia. Blood. 2011;118(20):5593-603.
70. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Nextgeneration sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116:3923-32.
71. Tefferi A. Mutational analysis in bcr-abl-negative classic myeloproliferative neoplasms: impact on prognosis and therapeuticchoices. Leuk Lymphoma. 2010;51:576-82.
72. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70:447-52.
73. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a jak2 mutation-positive myeloproliferativeneoplasm. Blood. 2010;115:2891-900.
74. Nguyen-Khac F, Lesty C, Eclache V, et al. Chromosomal abnormalities in transformed ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer. 2010;49:919-27.
75. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms.Blood. 2011;118:1723-35.
76. Kiladjian JJ, Masse A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatmenttargets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24:1519-23.
77. Couronne L, Lippert E, Andrieux J, et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia. 2010;24:201-3.